Physician profile
Jess L Boysen
NPI 1780862862
$2,954.72
in general payments reported to CMS, 2019-2025
14 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2021: $153 · 2022: $145 · 2023: $81.47 · 2024: $2,076 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,010.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $1,663.09 | 2024 | Iyuzeh |
| Alcon Vision LLC | $276.01 | 2022-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Glaukos Corporation | $259.07 | 2024-2025 | Idosetr, Radius Xr |
| New World Medical,INC. | $258.97 | 2024-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Aerie Pharmaceuticals, INC. | $146.20 | 2019 | |
| Allergan, INC. | $140.00 | 2021 | |
| Abbvie INC. | $47.90 | 2024 | |
| Horizon Therapeutics Plc | $42.71 | 2021-2022 | |
| Sight Sciences, INC. | $35.43 | 2022 | |
| Harrow Eye, LLC | $27.33 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $16.48 | 2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $15.69 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $12.94 | 2022 | |
| Rayner Intraocular Lenses Limited | $12.90 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Boysen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.